View in EDS

Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection.

Saved in:
Bibliographic Details
Title: Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection.
Authors: Kumar P; Department of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, USA., Mathayan M; Department of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, USA., Smieszek SP; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA., Przychodzen BP; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA., Koprivica V; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA., Birznieks G; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA., Polymeropoulos MH; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA., Prabhakar BS; Department of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, USA. Electronic address: bprabhak@uic.edu.
Source: Virology [Virology] 2022 Jul; Vol. 572, pp. 64-71. Date of Electronic Publication: 2022 May 16.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 0110674 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-0341 (Electronic) Linking ISSN: 00426822 NLM ISO Abbreviation: Virology Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35598394
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kumar+P%22">Kumar P</searchLink>; Department of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Mathayan+M%22">Mathayan M</searchLink>; Department of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Smieszek+SP%22">Smieszek SP</searchLink>; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA.<br /><searchLink fieldCode="AU" term="%22Przychodzen+BP%22">Przychodzen BP</searchLink>; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA.<br /><searchLink fieldCode="AU" term="%22Koprivica+V%22">Koprivica V</searchLink>; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA.<br /><searchLink fieldCode="AU" term="%22Birznieks+G%22">Birznieks G</searchLink>; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA.<br /><searchLink fieldCode="AU" term="%22Polymeropoulos+MH%22">Polymeropoulos MH</searchLink>; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA.<br /><searchLink fieldCode="AU" term="%22Prabhakar+BS%22">Prabhakar BS</searchLink>; Department of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, USA. Electronic address: bprabhak@uic.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220110674%22">Virology</searchLink> [Virology] 2022 Jul; Vol. 572, pp. 64-71. <i>Date of Electronic Publication: </i>2022 May 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Academic+Press%22">Academic Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0110674 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1096-0341 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200426822%22">00426822 </searchLink><i>NLM ISO Abbreviation: </i>Virology <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35598394
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.virol.2022.05.004
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 64
    Titles:
      – TitleFull: Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kumar P
      – PersonEntity:
          Name:
            NameFull: Mathayan M
      – PersonEntity:
          Name:
            NameFull: Smieszek SP
      – PersonEntity:
          Name:
            NameFull: Przychodzen BP
      – PersonEntity:
          Name:
            NameFull: Koprivica V
      – PersonEntity:
          Name:
            NameFull: Birznieks G
      – PersonEntity:
          Name:
            NameFull: Polymeropoulos MH
      – PersonEntity:
          Name:
            NameFull: Prabhakar BS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2022 Jul
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1096-0341
          Numbering:
            – Type: volume
              Value: 572
          Titles:
            – TitleFull: Virology
              Type: main
ResultId 1